Eniola's only viable angle at Upfront — if pursued at all — would require a complete reframing: position TOPOLOGIX (TDA for drug-protein interaction, hERG cardiotoxicity MVP) or IMPRINT (addiction-liability screening platform) as a US-incorporated deep-tech drug discovery startup seeking Seed investment, not as a research project. The Bionaut Labs precedent (CNS, drug delivery, LA-based) shows Upfront will occasionally back drug-adjacent companies, and Eniola's collaborators (Berridge/Michigan, Daw/Princeton) could lend scientific credibility as advisors. However, this would require: (1) incorporating a US LLC/C-corp immediately, (2) finding a US co-founder or technical lead already in the US, (3) translating the CCT model into a commercial SaaS drug-screening API product pitch with revenue projections — a multi-month pivot away from fellowship-seeking. This is not the right opportunity for Eniola at her current stage.